237 related articles for article (PubMed ID: 25281858)
21. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
22. Transforming Growth Factor-β Promotes Liver Tumorigenesis in Mice via Up-regulation of Snail.
Moon H; Ju HL; Chung SI; Cho KJ; Eun JW; Nam SW; Han KH; Calvisi DF; Ro SW
Gastroenterology; 2017 Nov; 153(5):1378-1391.e6. PubMed ID: 28734833
[TBL] [Abstract][Full Text] [Related]
23. Defects in long-chain 3-hydroxy acyl-CoA dehydrogenase lead to hepatocellular carcinoma: A novel etiology of hepatocellular carcinoma.
Khare T; Khare S; Angdisen JJ; Zhang Q; Stuckel A; Mooney BP; Ridenhour SE; Gitan RS; Hammoud GM; Ibdah JA
Int J Cancer; 2020 Sep; 147(5):1461-1473. PubMed ID: 32115688
[TBL] [Abstract][Full Text] [Related]
24. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis.
Tsai WC; Hsu SD; Hsu CS; Lai TC; Chen SJ; Shen R; Huang Y; Chen HC; Lee CH; Tsai TF; Hsu MT; Wu JC; Huang HD; Shiao MS; Hsiao M; Tsou AP
J Clin Invest; 2012 Aug; 122(8):2884-97. PubMed ID: 22820290
[TBL] [Abstract][Full Text] [Related]
26. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
27. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
[TBL] [Abstract][Full Text] [Related]
28. Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma.
Wright JH; Johnson MM; Shimizu-Albergine M; Bauer RL; Hayes BJ; Surapisitchat J; Hudkins KL; Riehle KJ; Johnson SC; Yeh MM; Bammler TK; Beyer RP; Gilbertson DG; Alpers CE; Fausto N; Campbell JS
Int J Cancer; 2014 Feb; 134(4):778-88. PubMed ID: 23929039
[TBL] [Abstract][Full Text] [Related]
29. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289
[TBL] [Abstract][Full Text] [Related]
30. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease.
Lechel A; Holstege H; Begus Y; Schienke A; Kamino K; Lehmann U; Kubicka S; Schirmacher P; Jonkers J; Rudolph KL
Gastroenterology; 2007 Apr; 132(4):1465-75. PubMed ID: 17433324
[TBL] [Abstract][Full Text] [Related]
31. Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors.
Gehrke N; Wörns MA; Huber Y; Hess M; Straub BK; Hövelmeyer N; Waisman A; Kim YO; Schuppan D; Galle PR; Schattenberg JM
J Hepatol; 2016 Dec; 65(6):1188-1197. PubMed ID: 27405060
[TBL] [Abstract][Full Text] [Related]
32. GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN.
Chen WT; Zhu G; Pfaffenbach K; Kanel G; Stiles B; Lee AS
Oncogene; 2014 Oct; 33(42):4997-5005. PubMed ID: 24141775
[TBL] [Abstract][Full Text] [Related]
33. Insulin resistance, steatohepatitis, and hepatocellular carcinoma in a new congenic strain of Fatty Liver Shionogi (FLS) mice with the Lep(ob) gene.
Soga M; Hashimoto S; Kishimoto Y; Hirasawa T; Makino S; Inagaki S
Exp Anim; 2010; 59(4):407-19. PubMed ID: 20660987
[TBL] [Abstract][Full Text] [Related]
34. EDIL3 is a novel regulator of epithelial-mesenchymal transition controlling early recurrence of hepatocellular carcinoma.
Xia H; Chen J; Shi M; Gao H; Sekar K; Seshachalam VP; Ooi LL; Hui KM
J Hepatol; 2015 Oct; 63(4):863-73. PubMed ID: 25980764
[TBL] [Abstract][Full Text] [Related]
35. SPARC inhibition accelerates NAFLD-associated hepatocellular carcinoma development by dysregulating hepatic lipid metabolism.
M Onorato A; Fiore E; Bayo J; Casali C; Fernandez-Tomé M; Rodríguez M; Domínguez L; Argemi J; Hidalgo F; Favre C; García M; Atorrasagasti C; Mazzolini GD
Liver Int; 2021 Jul; 41(7):1677-1693. PubMed ID: 33641248
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
37. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
38. The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease.
Lake AD; Novak P; Hardwick RN; Flores-Keown B; Zhao F; Klimecki WT; Cherrington NJ
Toxicol Sci; 2014 Jan; 137(1):26-35. PubMed ID: 24097666
[TBL] [Abstract][Full Text] [Related]
39. Tumor progression locus 2 ablation suppressed hepatocellular carcinoma development by inhibiting hepatic inflammation and steatosis in mice.
Li X; Liu C; Ip BC; Hu KQ; Smith DE; Greenberg AS; Wang XD
J Exp Clin Cancer Res; 2015 Nov; 34():138. PubMed ID: 26560698
[TBL] [Abstract][Full Text] [Related]
40. Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer.
Blanc V; Riordan JD; Soleymanjahi S; Nadeau JH; Nalbantoglu I; Xie Y; Molitor EA; Madison BB; Brunt EM; Mills JC; Rubin DC; Ng IO; Ha Y; Roberts LR; Davidson NO
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33445170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
